Gilead Sciences (GILD) Receivables - Other (2018 - 2025)
Gilead Sciences (GILD) has disclosed Receivables - Other for 8 consecutive years, with $629.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other rose 127.08% year-over-year to $629.0 million, compared with a TTM value of $629.0 million through Dec 2025, up 127.08%, and an annual FY2025 reading of $629.0 million, up 127.08% over the prior year.
- Receivables - Other was $629.0 million for Q4 2025 at Gilead Sciences, down from $695.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $695.0 million in Q3 2025 and bottomed at $9.0 million in Q1 2021.
- Average Receivables - Other over 5 years is $222.0 million, with a median of $167.0 million recorded in 2021.
- The sharpest move saw Receivables - Other crashed 93.57% in 2021, then skyrocketed 1677.78% in 2022.
- Year by year, Receivables - Other stood at $174.0 million in 2021, then dropped by 1.72% to $171.0 million in 2022, then crashed by 31.58% to $117.0 million in 2023, then surged by 136.75% to $277.0 million in 2024, then soared by 127.08% to $629.0 million in 2025.
- Business Quant data shows Receivables - Other for GILD at $629.0 million in Q4 2025, $695.0 million in Q3 2025, and $305.0 million in Q2 2025.